Regeneron Pharmaceuticals

Regeneron's PD-1 inhibitor Libtayo (cemiplimab) is now reimbursed by public drug programs in seven Canadian provinces for advanced non-small cell lung cancer and locally advanced basal cell carcinoma.

ModeX Therapeutics, an OPKO Health subsidiary, has entered into a license and collaboration agreement with Regeneron Pharmaceuticals to develop multispecific antibodies targeting multiple biological pathways simultaneously.

Regeneron's DB-OTO gene therapy demonstrated clinically meaningful hearing improvements in 11 of 12 patients with OTOF gene mutations within weeks of treatment.

Post hoc analysis of pooled BOREAS and NOTUS phase 3 trials demonstrates dupilumab's consistent efficacy in reducing COPD exacerbations by 31-33% regardless of cardiovascular or metabolic disease history.

Excellergy secured $70 million in Series A funding to develop first-in-class trifunctional Effector Cell Response Inhibitors (ECRIs) for allergic conditions.

Regeneron's investigational gene therapy DB-OTO demonstrated clinically meaningful hearing improvements in 11 of 12 children with profound genetic hearing loss due to OTOF gene variants in the pivotal CHORD trial.

Wall Street analysts predict Eli Lilly and AstraZeneca are the most likely pharmaceutical companies to strike the next drug pricing deal with the Trump administration following Pfizer's September 29 agreement.

Amgen's Phase III VESALIUS-CV trial met both primary endpoints, demonstrating that Repatha significantly reduces major adverse cardiovascular events in high-risk patients without prior heart attack or stroke.

MiNK Therapeutics has appointed Dr. Terese C. Hammond as Head of Inflammatory and Pulmonary Diseases to accelerate their invariant natural killer T (iNKT) cell therapy pipeline toward pivotal development.

Regeneron's Phase 3 OPTIMA trial of garetosmab met its primary endpoint, demonstrating a 90% or greater reduction in new heterotopic ossification lesions in adults with fibrodysplasia ossificans progressiva at 56 weeks.